NEW YORK, Dec. 03, 2015 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Valeant Pharmaceuticals International, Inc. (“Valeant Pharmaceuticals”) (NYSE:VRX) between February 23, 2015 and October 20, 2015.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information go to:
http://zlk.9nl.com/valeant-pharmaceuticals
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the Class Period, defendants made false and misleading statements and/or failed to disclose adverse information about the Company’s business and prospects, including that: (a) the Company was using a network of specialty mail-order pharmacies that it actually controlled to prop up sales of its high-priced drugs and to keep patients and their insurance companies from switching to less costly generic drugs; (b) that Valeant's undisclosed use of specialty pharmacies left it subject to increased regulatory risks; and (c) that without the use of the specialty pharmacies, Valeant’s financial performance and Class Period financial guidance would have been negatively impacted. As a result of these false and misleading statements and/or omissions, Valeant stock traded at artificially inflated prices during the Class Period, reaching over $260 per share.
If you suffered a loss in Valeant Pharmaceuticals you have until December 21, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 



